Amprenavir Patent Expiration
Amprenavir is Used for managing HIV infection. It was first introduced by Glaxosmithkline
Amprenavir Patents
Given below is the list of patents protecting Amprenavir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Agenerase | US6730679 | Pharmaceutical formulations |
Nov 11, 2017
(Expired) | Glaxosmithkline |
| Agenerase | US5723490 | THF-containing sulfonamide inhibitors of aspartyl protease |
Mar 03, 2015
(Expired) | Glaxosmithkline |
| Agenerase | US5646180 | Treatment of the CNS effects of HIV |
Jul 08, 2014
(Expired) | Glaxosmithkline |
| Agenerase | US5585397 | Sulfonamide inhibitors of aspartyl protease |
Dec 17, 2013
(Expired) | Glaxosmithkline |
Amprenavir's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Amprenavir:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction | Medical College of Wisconsin | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Oral Fosamprenavir for GERD | Medical College of Wisconsin | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen | Gilead Sciences | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2, PHASE3 |
| Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-infected Patients in Virological Failure. | ANRS, Emerging Infectious Diseases | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |